338 related articles for article (PubMed ID: 12433354)
1. [Clinical relevance of mechanisms of antifungal drug resistance in filamentous fungi].
Mellado E; Cuenca-Estrella M; Rodríguez-Tudela JL
Enferm Infecc Microbiol Clin; 2002 Dec; 20(10):523-29; quiz 530, 539. PubMed ID: 12433354
[TBL] [Abstract][Full Text] [Related]
2. [Antifungal drug].
Yamaguchi H
Nihon Rinsho; 2003 Feb; 61 Suppl 2():768-73. PubMed ID: 12722314
[No Abstract] [Full Text] [Related]
3. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.
Cuenca-Estrella M; Gomez-Lopez A; Mellado E; Buitrago MJ; Monzon A; Rodriguez-Tudela JL
Antimicrob Agents Chemother; 2006 Mar; 50(3):917-21. PubMed ID: 16495251
[TBL] [Abstract][Full Text] [Related]
4. Antifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside.
Cuenca-Estrella M
Clin Microbiol Infect; 2014 Jun; 20 Suppl 6():54-9. PubMed ID: 24372680
[TBL] [Abstract][Full Text] [Related]
5. [Antifungals cellular targets and mechanisms of resistance].
Accoceberry I; Noël T
Therapie; 2006; 61(3):195-9. PubMed ID: 16989119
[TBL] [Abstract][Full Text] [Related]
6. [New systemic antifungal drugs: mechanisms of action, drug interactions and side effects].
Schäfer-Korting M
Mycoses; 2003; 46 Suppl 1():28-31. PubMed ID: 12955850
[TBL] [Abstract][Full Text] [Related]
7. Update on antifungal therapy.
Grooters AM; Taboada J
Vet Clin North Am Small Anim Pract; 2003 Jul; 33(4):749-58, vi. PubMed ID: 12910741
[TBL] [Abstract][Full Text] [Related]
8. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
9. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
Jensen RH
Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
[TBL] [Abstract][Full Text] [Related]
10. In vitro evaluation of combination of terbinafine with itraconazole or amphotericin B against Zygomycota.
Gómez-López A; Cuenca-Estrella M; Mellado E; Rodríguez-Tudela JL
Diagn Microbiol Infect Dis; 2003 Mar; 45(3):199-202. PubMed ID: 12663161
[TBL] [Abstract][Full Text] [Related]
11. Caspofungin: the first representative of a new antifungal class.
Letscher-Bru V; Herbrecht R
J Antimicrob Chemother; 2003 Mar; 51(3):513-21. PubMed ID: 12615851
[TBL] [Abstract][Full Text] [Related]
12. Antifungal agents.
Chen SC; Sorrell TC
Med J Aust; 2007 Oct; 187(7):404-9. PubMed ID: 17908006
[TBL] [Abstract][Full Text] [Related]
13. [Antifungal agents in the treatment of systemic infections: Relevance of mechanism of action, activity profile and resistances].
Cuenca-Estrella M
Rev Esp Quimioter; 2010 Dec; 23(4):169-76. PubMed ID: 21191554
[TBL] [Abstract][Full Text] [Related]
14. Caspofungin acetate for treatment of invasive fungal infections.
Pacetti SA; Gelone SP
Ann Pharmacother; 2003 Jan; 37(1):90-8. PubMed ID: 12503942
[TBL] [Abstract][Full Text] [Related]
15. Antifungal susceptibilities of the species of the Pseudallescheria boydii complex.
Gilgado F; Serena C; Cano J; Gené J; Guarro J
Antimicrob Agents Chemother; 2006 Dec; 50(12):4211-3. PubMed ID: 17015631
[TBL] [Abstract][Full Text] [Related]
16. New antifungal agents.
Graybill JR
Eur J Clin Microbiol Infect Dis; 1989 May; 8(5):402-12. PubMed ID: 2546775
[TBL] [Abstract][Full Text] [Related]
17. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections.
Groll AH; Walsh TJ
Expert Opin Investig Drugs; 2001 Aug; 10(8):1545-58. PubMed ID: 11772269
[TBL] [Abstract][Full Text] [Related]
18. In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis.
Cuenca-Estrella M; Gomez-Lopez A; Buitrago MJ; Mellado E; Garcia-Effron G; Rodriguez-Tudela JL
Antimicrob Agents Chemother; 2006 Jun; 50(6):2248-50. PubMed ID: 16723597
[TBL] [Abstract][Full Text] [Related]
19. [The latest diagnosis and treatment on deep-seated mycosis. Expectations for micafungin, the first candin in Japan (discussion)].
Kohno S; Niki Y; Takematsu Y; Yoshida M
Jpn J Antibiot; 2003 Feb; 56(1):1-14. PubMed ID: 12723394
[No Abstract] [Full Text] [Related]
20. Caspofungin: a major breakthrough in treatment of systemic fungal infections.
Agarwal MB; Rathi SA; Ratho N; Subramanian R
J Assoc Physicians India; 2006 Dec; 54():943-8. PubMed ID: 17334012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
